Dendritic cell-derived exosomes: A new horizon in personalized cancer immunotherapy?. (28th May 2023) - Ghorbaninezhad, Farid
Abstract: Dendritic cells (DCs) release nanometer-sized membrane vesicles known as dexosomes, containing different molecules, particularly proteins, for presenting antigens, i.e., major histocompatibility complex (MHC)-I/II and CD86. Dexosomes can, directly and indirectly, stimulate antigen-reactive CD8 + and CD4 + T cell responses. Antigen-loaded dexosomes can lead to the development of potent anti-tumoral immune responses. Notably, developing dexosome-based cell-free vaccines could serve as a new vaccination platform in the era of immunotherapy for various cancers. Furthermore, combining dexosomes vaccination strategies with other treatment approaches can considerably increase tumor-specific T cell responses. Herein, we aimed to review how dexosomes interact with immune cells, e.g., CD4 + and CD8 + T cells and natural killer (NK) cells. Besides, we discussed the limitations of this approach and suggested potential strategies to improve its effectiveness for affected patients. Highlights: DC-secreted exosomes called dexosomes, playing a role in cancer immunotherapy. Dexosome-based therapies were beneficial in (pre)clinical investigations. Presence of MHC-I/II and costimulatory molecules on dexosomes stimulate immune cells.